Skip to content

Try berberine, leg press, retatrutide or HbA1c.

    ← Peptide library

    Gut barrier

    Larazotide

    Also known as Larazotide acetate, AT-1001, INN-202

    InvestigationalHuman clinical evidence

    Investigational; not approved. Its phase 3 celiac trial was stopped in 2022 after an interim analysis

    In simple words: An experimental oral peptide that helps close the gaps between the cells lining your gut, so less of what's in your gut leaks into your blood (“leaky gut”).

    How it works

    The cells of your gut lining are held together by “tight junctions”. A protein called zonulin opens them; gluten triggers zonulin in people with celiac disease. Larazotide blocks zonulin's effect and helps reorganize the tight-junction proteins, closing those gaps. It works inside the gut and very little reaches the blood. When the lining leaks, food particles, toxins and microbes can reach the bloodstream and keep the immune system switched on, which is linked to low-grade inflammation, joint and skin problems, brain fog and metabolic strain. Whether leaky gut causes those conditions or results from them is still being studied.

    Targets: Tight junctions of the gut lining, Zonulin signalling · Class: Oral 8-amino-acid peptide; tight-junction regulator (zonulin antagonist)

    Uses, latest studies & pairings

    Typically used for

    • “Leaky gut” (intestinal permeability): helping seal the gaps between the cells of the gut lining.
    • Celiac disease: the only condition it has been tested for in people, as an add-on to a gluten-free diet.
    • Sold by some clinics and online as oral capsules for gut inflammation; those products are unregulated.

    Commonly paired with

    • BPC-157 and KPV, as a “gut stack”: popular online, but the combination has never been studied.
    • Lactoferrin, butyrate, fiber and a gut-friendly diet as everyday gut-lining support (see the Vitamins page).
    • A strict gluten-free diet if you have celiac disease; larazotide was only tested on top of it.

    Latest studies & news

    1. 2025

      Lab study: protected the gut lining from low-oxygen injury, stabilized tight junctions and helped cells recover.

      Source: Kim et al. Biomedicines 2025
    2. 2022

      The phase 3 celiac trial (CeDLara) was stopped after an interim analysis suggested it wouldn't meet its goal. No newer human trials have been reported.

      Source: ClinicalTrials.gov NCT03569007
    3. 2015

      Phase 2b (342 adults with celiac disease on a gluten-free diet): the lowest dose reduced symptoms; higher doses didn't.

      Source: Leffler et al. Gastroenterology 2015
    ▶ Videos about Larazotide (8)

    What the research shows

    Human clinical evidence

    Human
    • Celiac disease, gluten challenge (184 adults): 0.25 mg reduced gluten-triggered symptoms versus placebo; the gut-permeability test didn't clearly improve (Leffler 2012).
    • Celiac disease, gluten challenge (86 adults): reduced gluten-triggered immune activity and gut symptoms, though the permeability measure was inconclusive (Kelly 2013).
    • Celiac disease on a gluten-free diet with ongoing symptoms (342 adults, phase 2b): the lowest dose, 0.5 mg three times a day, reduced symptoms; higher doses didn't beat placebo (Leffler 2015).
    • Phase 3 (CeDLara, NCT03569007): stopped by the sponsor in 2022 after an interim analysis suggested it wouldn't meet its goal. It has never been tested for “leaky gut” outside celiac disease.

    Laboratory / in-vitro

    In-vitro
    • Lab and animal work: it stabilizes tight junctions, protects the gut lining after low-oxygen injury and helps cells recover (Kim 2025).
    • Review of how it regulates tight junctions as a zonulin antagonist (Slifer 2021).

    Animal and lab results suggest what might happen; they don't prove an effect in people.

    Safety & what to watch

    • Well tolerated in trials of up to 12 weeks; side effects were similar to placebo.
    • Not approved anywhere. Capsules sold online or by clinics are unregulated, and their contents and dose are unverified.
    • Celiac disease still needs a strict gluten-free diet; larazotide was only ever studied as an add-on.

    Amounts

    No dose is given for unapproved substances. If you are considering it, discuss it with a licensed clinician who knows your history and bloodwork.

    Studies & references

    Draft profile pending editorial review. Educational only, not medical advice. Never start, stop or change a medicine without your prescriber.